Who is sponsoring NCT04220450?

NCT04220450 is sponsored by Dr. Andreas Kammerlander.

What drugs are being tested in NCT04220450?

Interventions in NCT04220450: T1 mapping on Cardiovascular Magnetic Resonance Studies.

What condition does NCT04220450 study?

NCT04220450 studies NAFLD, Heart Failure, Valvular Disease, Coronary Disease.

Is NCT04220450 still recruiting?

NCT04220450 is currently status unknown. Last updated 7 January 2020.

Last reviewed 2020-01-07 · How we verify

NCT04220450

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

T1-mapping by Cardiovascular Magnetic Resonance Imaging to Assess Non-Alcoholic Fatty Liver Disease

Status unknown Last updated 7 January 2020

What this trial tests

trial testing T1 mapping on Cardiovascular Magnetic Resonance Studies in NAFLD in 800 participants. Status unknown.

Timeline

1 June 2020

Primary endpoint
1 June 2021

15 June 2021

Quick facts

Lead sponsor	Dr. Andreas Kammerlander
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	800
Start date	1 June 2020
Primary completion	1 June 2021
Estimated completion	15 June 2021
Sites	1 location across Austria

Drugs / interventions tested

T1 mapping on Cardiovascular Magnetic Resonance Studies

Conditions studied

NAFLD — all drugs for NAFLD →
Heart Failure — all drugs for Heart Failure →
Valvular Disease — all drugs for Valvular Disease →
Coronary Disease — all drugs for Coronary Disease →

Sponsor

Dr. Andreas Kammerlander

Who can join

18 Months and older, any sex, with NAFLD or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

On clinically indicated Cardiovascular Magnetic Resonance studies, native T1-times and extracellular volume of the liver will be assessed and findings correlated with established risk calculators for non-alcoholic fatty liver disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Hepatic T1-Time Predicts Cardiovascular Risk in All-Comers Referred for Cardiovascular Magnetic Resonance: A Post-Hoc Analysis.
Mascherbauer K, Donà C, Koschutnik M, Dannenberg V, et al · · 2022 · cited 8× · PMID 36256728 · DOI 10.1161/circimaging.122.014716

Verify or expand the search:

Other recruiting trials for NAFLD

Currently open trials in the same condition.

NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
NCT06661655 — Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients · NA · recruiting
NCT07093346 — The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patient · NA · recruiting
NCT06879236 — Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease · recruiting
NCT06888310 — Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04220450 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dr. Andreas Kammerlander
Last refreshed: 7 January 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04220450.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing